These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25625848)

  • 1. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.
    Hallberg AR; Vorrink SU; Hudachek DR; Cramer-Morales K; Milhem MM; Cornell RA; Domann FE
    Epigenetics; 2014 Dec; 9(12):1641-7. PubMed ID: 25625848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
    Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
    Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
    Liu S; Ren S; Howell P; Fodstad O; Riker AI
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of the thrombomodulin gene in human malignant melanoma.
    Furuta J; Kaneda A; Umebayashi Y; Otsuka F; Sugimura T; Ushijima T
    Melanoma Res; 2005 Feb; 15(1):15-20. PubMed ID: 15714116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
    Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
    Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth.
    Xu M; Chen X; Chen N; Nie L; Li X; Li Q; Zeng H; Zhou Q
    Am J Pathol; 2013 Jan; 182(1):84-95. PubMed ID: 23159945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
    Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of metallothionein 1A gene in melanoma.
    Nobeyama Y; Nakagawa H
    J Dermatol Sci; 2017 Nov; 88(2):232-237. PubMed ID: 28764861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
    Venza M; Visalli M; Biondo C; Lentini M; Catalano T; Teti D; Venza I
    Biochim Biophys Acta; 2015 Mar; 1849(3):247-56. PubMed ID: 25497382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant p27Kip1 promoter methylation in malignant melanoma.
    Worm J; Bartkova J; Kirkin AF; Straten P; Zeuthen J; Bartek J; Guldberg P
    Oncogene; 2000 Oct; 19(44):5111-5. PubMed ID: 11042700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation.
    Stengel S; Fiebig U; Kurth R; Denner J
    Genes Chromosomes Cancer; 2010 May; 49(5):401-11. PubMed ID: 20095041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
    Furuta J; Nobeyama Y; Umebayashi Y; Otsuka F; Kikuchi K; Ushijima T
    Cancer Res; 2006 Jun; 66(12):6080-6. PubMed ID: 16778180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
    Wang H; Lee S; Nigro CL; Lattanzio L; Merlano M; Monteverde M; Matin R; Purdie K; Mladkova N; Bergamaschi D; Harwood C; Syed N; Szlosarek P; Briasoulis E; McHugh A; Thompson A; Evans A; Leigh I; Fleming C; Inman GJ; Hatzimichael E; Proby C; Crook T
    Br J Cancer; 2012 Apr; 106(8):1446-52. PubMed ID: 22454080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
    Nobeyama Y; Okochi-Takada E; Furuta J; Miyagi Y; Kikuchi K; Yamamoto A; Nakanishi Y; Nakagawa H; Ushijima T
    Int J Cancer; 2007 Jul; 121(2):301-7. PubMed ID: 17372906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
    Pulukuri SM; Rao JS
    Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation status of multiple genes in uveal melanoma.
    Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
    Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
    Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
    Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
    Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
    Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.